EVH Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

469.68M

-27.35%

0.051

-355.9%

547.31M

+13.16%

0.052

-12.87%

591.66M

+33.16%

0.056

-156.19%

Estimates Revision

The market is revising Downward the revenue expectations for Evolent Health, Inc. (EVH) for FY2025, with the revenue forecasts being adjusted by -0.34% over the past three months. During the same period, the stock price has changed by -48.32%.

Revenue Estimates for FY2025

Revise Downward

-0.34%

In Past 3 Month

EPS Estimates for FY2025

Revise Downward

-71.76%

In Past 3 Month

Stock Price

Go Down

-48.32%

In Past 3 Month

13 Analyst Rating

Wall Street analysts forecast EVH stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for EVH is 10.14 USD with a low forecast of 7.00 USD and a high forecast of 16.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

13 Buy

0 Hold

0 Sell

Strong Buy

Current: 0.000

Low

7.00

Averages

10.14

High

16.00

Current: 0.000

Low

7.00

Averages

10.14

High

16.00

Citi

Buy

downgrade

2025-11-21

Reason

Citi

Price Target

2025-11-21

downgrade

Buy

Reason

Citi lowered the firm's price target on Evolent Health to $9.50 from $11.50 and keeps a Buy rating on the shares.

JPMorgan

Overweight -> NULL

downgrade

$13 -> $7

2025-11-17

Reason

JPMorgan

Price Target

$13 -> $7

2025-11-17

downgrade

Overweight -> NULL

Reason

JPMorgan lowered the firm's price target on Evolent Health to $7 from $13 and keeps an Overweight rating on the shares. The firm updated the company's model.

Canaccord

Buy

downgrade

$16 -> $9

2025-11-14

Reason

Canaccord

Price Target

$16 -> $9

2025-11-14

downgrade

Buy

Reason

Canaccord lowered the firm's price target on Evolent Health to $9 from $16 and keeps a Buy rating on the shares. The firm lowered its target by removing the premium valuation it had previously as the uncertainty on how ACA open enrollment will turn out as the shutdown ends without action on extending enhanced subsidies has put shares in limbo until more clarity emerges once open enrollment is completed. This and uncertainty on MA and Medicaid membership changes are holding the stock hostage near-term and overshadowing longer-term reasons to invest in Evolent.

Evolent Health

Stephens

Equal Weight -> Overweight

upgrade

2025-11-13

Reason

Evolent Health

Stephens

Price Target

2025-11-13

upgrade

Equal Weight -> Overweight

Reason

Stephens upgraded Evolent Health to Overweight from Equal Weight with an unchanged price target of $7.

Stephens

Equal Weight

Overweight

upgrade

2025-11-13

Reason

Stephens

Price Target

2025-11-13

upgrade

Equal Weight

Overweight

Reason

As previously reported, Stephens upgraded Evolent Health to Overweight from Equal Weight with an unchanged price target of $7 after Q3 beat expectations. The firm thought the print was enough for stabilization given already weak sentiment, but fears over 2026 uncertainty weighed on shares and the subsequent end of the government shutdown without a subsidy extension has confirmed what Evolent was already baking into 2026 expectations, the analyst tells investors. The firm contends that sentiment is at or near the bottom, the business is in "a better spot fundamentally than it was a year ago, or even at the start of this year," and that the growth opportunity set is "better than it has been in several years."

Oppenheimer

Outperform

NULL

downgrade

$18 -> $12

2025-11-12

Reason

Oppenheimer

Price Target

$18 -> $12

2025-11-12

downgrade

Outperform

NULL

Reason

Oppenheimer lowered the firm's price target on Evolent Health to $12 from $18 and keeps an Outperform rating on the shares following quarterly results. Management provided visibility into 2026 revenue of $2.5B, which reflects $550M of new contract impact. Though the company continues to boast an attractive pipeline of growth, the near-term outlook remains subjected to the uncertainty around Medicare Advantage and the ACA, adds Oppenheimer.

Valuation Metrics

The current forward P/E ratio for Evolent Health Inc (EVH.N) is 16.41, compared to its 5-year average forward P/E of 28.93. For a more detailed relative valuation and DCF analysis to assess Evolent Health Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

28.93

Current PE

16.41

Overvalued PE

294.43

Undervalued PE

-236.57

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

5Y Average EV/EBITDA

20.87

Current EV/EBITDA

9.44

Overvalued EV/EBITDA

29.58

Undervalued EV/EBITDA

12.16

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

5Y Average PS

1.42

Current PS

0.19

Overvalued PS

2.07

Undervalued PS

0.77

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

EVH News & Events

Events Timeline

No data

News

5.0

01-02Newsfilter

Evolent Health Appoints New CFO Mario Ramos with $2.35M Stock Award

5.0

01-02PRnewswire

Evolent Health Grants CFO Mario Ramos $2.35M Inducement Award

4.0

2025-12-16Yahoo Finance

Evolent Health (EVH) Faces Downgrade from Canaccord Due to Rising Short-Term Uncertainty and Confusion in Medicare/Medicaid Enrollment

People Also Watch

Frequently Asked Questions

What is Evolent Health Inc (EVH) stock price today?

The current price of EVH is 4.16 USD — it has increased 0.24 % in the last trading day.

What is Evolent Health Inc (EVH)'s business?

Evolent Health, Inc. is a health care company connecting care for people with complex conditions like cancer, cardiovascular disease, and musculoskeletal diagnoses. The Company offers primary solutions, including specialty care management services and administrative services. It provides comprehensive quality management for oncology and cardiology patients from diagnosis through advanced care planning services, as well as identifying quality, lowest cost of care for outpatient orthopedic surgeries. Its administrative services solution includes an integrated value-based care platform designed to help customers manage and administer patient health in a cost-effective manner.

What is the price predicton of EVH Stock?

What is Evolent Health Inc (EVH)'s revenue for the last quarter?

Evolent Health Inc revenue for the last quarter amounts to 479.53M USD, decreased -22.83 % YoY.

What is Evolent Health Inc (EVH)'s earnings per share (EPS) for the last quarter?

Evolent Health Inc. EPS for the last quarter amounts to -0.24 USD, decreased -11.11 % YoY.

What changes have occurred in the market's expectations for Evolent Health Inc (EVH)'s fundamentals?

How many employees does Evolent Health Inc (EVH). have?

Evolent Health Inc (EVH) has 4500 emplpoyees as of January 09 2026.

What is Evolent Health Inc (EVH) market cap?

Today EVH has the market capitalization of 464.26M USD.